Intranasal corticosteroids: The role of patient preference and satisfaction

Allergy and Asthma Proceedings

Volumn 35, Issue 1, 2014, Pages 24-33

  Sher, Ellen R ^a   Ross, Jacqueline A ^a  

^a Atlantic Allergy Asthma and Immunology of NJ LLC ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CICLESONIDE; CORTICOSTEROID; FLUORINATED HYDROCARBON; FLUTICASONE FUROATE; FLUTICASONE PROPIONATE; MOMETASONE FUROATE; TRIAMCINOLONE ACETONIDE;

AEROSOL; ALLERGIC RHINITIS; ARTICLE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; PATIENT COMPLIANCE; PATIENT PREFERENCE; PATIENT SATISFACTION;

ADRENAL CORTEX HORMONES; ANTI-ALLERGIC AGENTS; DELIVERY OF HEALTH CARE; HEALTH CARE COSTS; HUMANS; MEDICATION ADHERENCE; PATIENT PREFERENCE; PERSONAL SATISFACTION; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; RISK FACTORS;

EID: 84893359018     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2014.35.3725     Document Type: Article

References (38)

1. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: An updated practice parameter. J Allergy Clin Immunol 122(suppl):S1- 84, 2008.
2. D̀Alonzo Jr. GE. Scope and impact of allergic rhinitis. J Am Osteopath Assoc 102(suppl 2):S2-S6, 2002.
3. Settipane RA, and Charnock DR. Epidemiology of rhinitis: Allergic and nonallergic. Clin Allergy Immunol 19:23-34, 2007.
4. Stokes M, Amorosi SL, Thompson D, et al. Evaluation of patients̀ preferences for triamcinolone acetonide aqueous, fluticasone propionate, and mometasone furoate nasal sprays in patients with allergic rhinitis. Otolaryngol Head Neck Surg 131: 225-231, 2004.
5. Weiner JM, Abramson MJ, and Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: Systematic review of randomised controlled trials. BMJ 317: 1624-1629, 1998.
6. Yáñ ez A, and Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: A systematic review with meta-analysis. Ann Allergy Asthma Immunol 89:479-484, 2002.
7. Howarth PH. A comparison of the anti-inflammatory properties of intranasal corticosteroids and antihistamines in allergic rhinitis. Allergy 55(suppl 62):6 -11, 2000.
8. Wiseman LR, and Benfield P. Intranasal fluticasone propionate. A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis. Drugs 53:885-907, 1997.
9. Horne R. Compliance, adherence, and concordance: Implications for asthma treatment. Chest 130(suppl 1):65S-72S, 2006.
10. Bukstein D, Luskin AT, and Farrar JR. The reality of adherence to rhinitis treatment: Identifying and overcoming the barriers. Allergy Asthma Proc 32:265-271, 2011.
11. Luskin AT, Blaiss MS, Farrar JR, et al. Is there a role for aerosol nasal sprays in the treatment of allergic rhinitis: A white paper. Allergy Asthma Proc 32:168 -177, 2011.
12. Bachert C, and El-Akkad T. Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol 89:292-297, 2002.
13. Mahadevia PJ, Shah S, Leibman C, et al. Patient preferences for sensory attributes of intranasal corticosteroids and willingness to adhere to prescribed therapy for allergic rhinitis: A conjoint analysis. Ann Allergy Asthma Immunol 93:345-350, 2004.
14. Hankin CS, Cox L, Lang D, et al. Medical costs and adherence in patients receiving aqueous versus pressurized aerosol formulations of intranasal corticosteroids. Allergy Asthma Proc 33:258 -264, 2012.
15. Corrigan JM, Kohn LT, Donaldson MS, et al. Improving the 21st-century health care system. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, D.C.: National Academy Press, 39-60, 2001.
16. Gazmararian JA, Kripalani S, Miller MJ, et al. Factors associated with medication refill adherence in cardiovascular-related diseases: A focus on health literacy. J Gen Intern Med 21:1215-1221, 2006.
17. Ngoh LN. Health literacy: A barrier to pharmacist-patient communication and medication adherence. J Am Pharm Assoc (2003) 49:e132- e146, 2009.
18. Kaliner MA. Patient preferences and satisfaction with prescribed nasal steroids for allergic rhinitis. Allergy Asthma Proc 22(suppl 1):S11-S15, 2001.
19. Schulman, Ronca and Bucuvalas, Inc. (SRBI) Allergies in America: A Landmark Survey of Nasal Allergy Sufferers. Available online at www.myallergiesinamerica.com; accessed June 7, 2007.
20. The National Allergy Survey Assessing Limitations (NASAL): Materials and respondent characteristics. J Fam Pract 61(suppl): S29-S33, 2012.
21. Gerson I, Green L, and Fishken D. Patient preference and sensory comparisons of nasal spray allergy medications. J Sens Stud 14:491-496, 1999.
22. Ricard N, Kind P, Christian S, et al. Link between patient preferences and treatment outcomes in seasonal allergic rhinitis: An empiric investigation. Clin Ther 21:268-277, 1999.
23. Silvers WS, Cohen R, D̀Alonzo G, et al. Comparative taste evaluation of aerosolized formulations of triamcinolone acetonide, flunisolide and flunisolide with menthol. Clin Ther 15:988-993, 1993.
24. Herman H. Once-daily administration of intranasal corticosteroids for allergic rhinitis: A comparative review of efficacy, safety, patient preference, and cost. Am J Rhinol 21:70-79, 2007.
25. Gross G, Jacobs RL, Woodworth TH, et al. Comparative efficacy, safety, and effect on quality of life of triamcinolone acetonide and fluticasone propionate aqueous nasal sprays in patients with fall seasonal allergic rhinitis. Ann Allergy Asthma Immunol 89:56-62, 2002.
26. Berger WE, Kaiser H, Gawchik SM, et al. Triamcinolone acetonide aqueous nasal spray and fluticasone propionate are equally effective for relief of nasal symptoms in patients with seasonal allergic rhinitis. Otolaryngol Head Neck Surg 129:16-23, 2003.
27. Shah SR, Miller C, Pethick N, et al. Two multicenter randomized, single-blind, single-dose, crossover studies of specific sensory attributes of budesonide aqueous nasal spray and fluticasone propionate nasal spray. Clin Ther 25:2198-2214, 2003.
28. Meltzer EO, Bardelas J, Goldsobel A, and Kaiser H. A preference evaluation study comparing the sensory attributes of mometasone furoate and fluticasone propionate nasal sprays by patients with allergic rhinitis. Treat Respir Med 4:289-296, 2005.
29. Meltzer EO, Stahlman JE, Leflein J, et al. Preferences of adult patients with allergic rhinitis for the sensory attributes of fluticasone furoate versus fluticasone propionate nasal sprays: A randomized, multicenter, double-blind, single-dose, crossover study. Clin Ther 30:271-279, 2008.
30. Meltzer EO, Andrews C, Journeay GE, et al. Comparison of patient preference for sensory attributes of fluticasone furoate or fluticasone propionate in adults with seasonal allergic rhinitis: A randomized, placebo-controlled, double-blind study. Ann Allergy Asthma Immunol 104:331-338, 2010.
31. Berger WE, Prenner B, Turner R, and Meltzer EO. A patient preference and satisfaction study of ciclesonide nasal aerosol and mometasone furoate aqueous nasal spray in patients with perennial allergic rhinitis. Allergy Asthma Proc 34:542- 550, 2013.
32. Meltzer EO, Ratner P, Testa M, et al. Satisfaction with and preference for ciclesonide hydrofluoroalkane nasal aerosol or mometasone furoate monohydrate aqueous nasal spray in patients with perennial allergic rhinitis: Results from a validation study. American Academy of Allergy, Asthma, and Immunology Annual Meeting, Orlando, FL March 2- 6, 2012.
33. Turner RR, Testa MA, Hayes JF, and Maxwell Su. Validation of the allergic rhinitis treatment satisfaction and preference scale. Allergy Asthma Proc 34:551-557, 2013.
34. Gross GN, Settipane RA, Ford LB, et al. Patient satisfaction with beclomethasone dipropionate nasal aerosol device with integrated dose counter during daily use. Allergy Asthma Proc 34:527-533, 2013.
35. Kohli E, and Buller A. Factors influencing consumer purchasing patterns of generic versus brand name over-the-counter drugs. South Med J 106:155-160, 2013.
36. Shrank WH, Cox ER, Fischer MA, et al. Patients̀ perceptions of generic medications. Health Aff (Millwood) 28:546-556, 2009.
37. Blaiss MS, Benninger MS, Fromer L, et al. Expanding choices in intranasal steroid therapy: Summary of a roundtable meeting. Allergy Asthma Proc 27:254-264, 2006.
38. Storms WW. Introduction: Patient preference of inhaled nasal corticosteroids. Allergy Asthma Proc 22(suppl 1):S1-S3, 2001.